Rose McNulty

The approval was supported by the pivotal phase 3 THRIVE and THRIVE-2 trials, which evaluated veligrotug in active and chronic TED.

The approach of pairing an ecological framework with AI methods offers a new way to identify where diabetes risk concentrates.

Age, skin phototype, and personal history of skin cancer are easily captured data elements that could form the basis of a practical, risk-stratified approach to surveillance.

The two conditions can have similar manifestations but differ in prognosis and treatment, which makes an accurate, early diagnosis important.

An electronic health record–based diabetes risk tool helped primary care teams target prevention and reduce progression to type 2 diabetes in prediabetes patients.

A genome-first study found familial melanoma gene variants exceed the genetic testing threshold in patients with multiple or early melanomas.

Thomas Martens, M.D., explains what drives adoption and how CONNECT's Level A evidence could move CGM coverage.

Thomas Martens, M.D., on why outcomes with CGM in CONNECT—including five more hours per day in range—came largely from lifestyle change, not added medication.

Thomas Martens, M.D., explains why CONNECT's 1.6% A1C reduction with continuous glucose monitoring is so exciting in patients with type 2 diabetes not on insulin.

A fully remote genetic screening program and a multicenter quality improvement initiative both advanced early type 1 diabetes detection.

Evolocumab cut major cardiac events by 29% in high-risk diabetes without prior heart attack or stroke in VESALIUS-CV subgroup data from ADA 2026.

Survodutide's SYNCHRONIZE trials show weight loss driven by visceral and liver fat, not muscle.

Artificial intelligence models matched mid-career dermatologists but trailed seasoned experts in diagnosing skin lesions across real-world cases.

An electronic health record–based model could help health systems target diabetes prevention to the high-risk patients most likely to benefit.

The REIMAGINE 1, 2 and 3 trials each met their primary HbA1c end point and confirmatory secondary end points for body weight reduction.

Phase 3 data show survodutide reduced liver fat by 63% and visceral fat by 34% — effects investigators say go beyond what weight loss alone explains.

The experimental glucagon/GLP-1 dual agonist showed targeted reductions in metabolically harmful fat alongside meaningful weight loss in two distinct patient populations.

The first triple hormone receptor agonist to reach phase 3 development demonstrated results that researchers say could reshape how clinicians approach obesity and type 2 diabetes treatment.

Results presented at ADA 2026 mark the first Level A evidence supporting CGM use in this population.

Joanne Mortimer, M.D., of City of Hope breaks down new data linking GLP-1 receptor agonist use to a reduction in mortality across multiple tumor types.

RASolute 302 shows daraxonrasib boosts survival in pancreatic cancer, with expanded access and trials pushing earlier use and combination strategies.

Daraxonrasib, a first-in-class multi-RAS inhibitor, doubles survival in metastatic pancreatic cancer and hints at broader, mutation-agnostic impact.

Tanya Dorff, M.D., breaks down early ABBV-969 data showing strong responses in heavily pretreated mCRPC at ASCO 2026.

Javier Cortes, M.D., Ph.D., discusses KEYNOTE-522 findings showing pembrolizumab plus chemotherapy delivers durable survival gains in high-risk early-stage TNBC after nearly 8 years of follow-up.

Lead ARACOG trial investigator Alicia Morgans, M.D., discusses the importance of including cognitive effects in the conversation around prostate cancer treatment.

New research highlights the role of a factual tone, credible sources, and clinician voices in vaccine-related social media.

Seven-year CROWN trial data show lorlatinib's median PFS still not reached in advanced ALK-positive NSCLC, with a 94% reduction in intracranial progression risk.

A CDC study found people vaccinated within the past six months were nearly half as likely to transmit SARS-CoV-2 to those they live with.

The advent of checkpoint inhibitors has altered the treatment landscape in urothelial bladder cancer, said Arlene O. Siefker-Radtke, MD, during last week’s NCCN Conference.